Learn More
Treatment of chronic myeloid leukemia (CML) has seen dramatic progress in recent years with the development of tyrosine kinase inhibitors (TKIs). To take maximum advantage of therapy with TKIs, compliance and good understanding of monitoring response to therapy are essential. We established a team that included a hematologist, a physician assistant (PA),(More)
Dasatinib (DAS) is a well tolerated oral dual SRC inhibitor with remarkable activity against all phases of imatinib-resistant chronic myeloid leukemia (CML). This paper focuses on the activity of DAS in intractable CML, and reviews outcomes of patients enrolled on DAS clinical trials. Safety and tolerability as well as practical tips for management of(More)
A multidisciplinary approach offers efficiency and quality care by delegating tasks according to individuals' expertise. However, increasingly stringent regulatory requirements, albeit essential for successful conduct of clinical trials, have magnified the workload of research teams. We describe tools that have efficiently addressed regulatory requirements(More)
  • 1